Men’s Health

FDA has received about 30 reports of sudden hearing loss in patients taking a class of erectile dysfunction drugs called PDE5 inhibitors

New research results suggest that a hormone therapy, commonly used to treat prostate cancer, called androgen-deprivation therapy may increase the risk of diabetes, particularly in obese men and patients should be made aware of this.

The FDA warned healthcare professionals that sudden loss of hearing has been reported in patients taking phosphodiesterase 5 (PDE-5) inhibitors.

As epidemiologic evidence suggests diabetic men have a slightly lower prostate cancer risk than non-diabetic men.

A new study sheds additional light on how erectile dysfunction (ED) interacts with diabetes. The study is another step in uncovering the link between the two disorders, and may lead to improved efficacy in erectile dysfunction treatments.

Having type 2 diabetes may have one benefit, in that men with long-term diabetes may have a reduced risk of prostate cancer, according to the results of a study published in the American Journal of Epidemiology.

Researchers report that, BPH, or benign prostate hyperplasia, is a common condition in older men, but the risk of developing the condition seems to be increased by obesity and high blood sugar levels,.

Regardless of the reason for taking them, painkillers classified as non-steroidal anti-inflammatory drugs (NSAIDs) apparently increase the likelihood that middle-aged and elderly men will develop erection difficulties, according to a new report.

Gonadotropin-releasing hormone (GnRH) agonist treatment for prostate cancer appears to increase the chances of diabetes development, according to Boston-based researchers.

Erectile dysfunction is an early sign of cardiovascular troubles down the road, such as a stroke or heart attack.